Agile Therapeutics Inc
General ticker "AGRX" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $8.4M
Agile Therapeutics Inc does not follow the US Stock Market performance with the rate: -29.3%.
Estimated limits based on current volatility of 0.9%: low 1.49$, high 1.52$
Factors to consider:
- Earnings for 18 months up through Q2 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2022-12-31 to 2024-12-30
- 2022-12-31 to 2023-12-31 estimated range: [6.25$, 20.82$]
- 2023-12-31 to 2024-12-30 estimated range: [5.03$, 14.27$]
Financial Metrics affecting the AGRX estimates:
- Negative: Non-GAAP EPS of -345.00 <= 0.08
- Negative: Operating Income to Revenue ratio of -1.00 <= 0.01
- Negative: negative Net Income
- Negative: Operating Cash Flow per share of -83.17 <= 0.20
- Negative: Industry Operating Cash Flow per share (median) of -0.72 <= 0.28
- Negative: Industry Earnings per Price (median) of -0.21 <= 0.01
- Negative: Interest Expense per share of 7.24 > 0.85
Short-term AGRX quotes
Long-term AGRX plot with estimates
Financial data
| YTD | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|
| Operating Revenue | $0.75MM | $4.10MM | $0.00MM |
| Operating Expenses | $49.80MM | $75.11MM | $52.56MM |
| Operating Income | $-49.05MM | $-71.00MM | $-52.56MM |
| Non-Operating Income | $-2.80MM | $-0.06MM | $22.47MM |
| Interest Expense | $3.11MM | $3.91MM | $3.13MM |
| R&D Expense | $13.50MM | $6.25MM | $3.25MM |
| Income(Loss) | $-51.85MM | $-71.07MM | $-30.09MM |
| Taxes | $0.00MM | $0.00MM | $-4.67MM |
| Profit(Loss) | $-51.85MM | $-71.07MM | $-25.41MM |
| Stockholders Equity | $49.33MM | $3.92MM | $-5.54MM |
| Assets | $73.06MM | $39.33MM | $14.24MM |
| Operating Cash Flow | $-47.31MM | $-65.20MM | $-35.95MM |
| Investing Cash Flow | $-40.69MM | $39.46MM | $-0.13MM |
| Financing Cash Flow | $67.98MM | $30.42MM | $22.18MM |
| Earnings Per Share* | $-1,291.56 | $-63,115.49 | $-58.79 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.